Glutamine
What studies of glutamine found
At a glance, by condition
ME/CFS: D Little or no difference
Based on the strongest evidence, studies with no comparison group (very low certainty): 3 findings, all D.
3 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Studies found little or no difference with glutamine for ME/CFS. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- CMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- Glutamine · ME/CFS is hereDLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
ME/CFS
Cognition (brain fog)1 study · 8 (few people) people took glutamine Little or no difference D
Why this grade: Little or no difference, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (8 in all).
Studies with no comparison group16 randomised · 26 weeks · 2000 mg, daily (few people)
No clear change in cognition (brain fog).
The evidence is very uncertain about the effect of glutamine on cognition (brain fog) in ME/CFS. Little or no difference · very low certainty D
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (8 in all)
See the 1 study
-
The Role of Glutamine in the Aetiology of the Chronic Fatigue Syndrome (1998)
- People in the study
- 16 randomised
- Dose
- 2000 mg, daily
- Outcome
- Concentration Difficulties
- Effect
- no clear difference
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Low mood or anxiety1 study · 8 (few people) people took glutamine Little or no difference D
Why this grade: Little or no difference, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (8 in all).
Studies with no comparison group16 randomised · 26 weeks · 2000 mg, daily (few people)
No clear change in low mood or anxiety.
The evidence is very uncertain about the effect of glutamine on low mood or anxiety in ME/CFS. Little or no difference · very low certainty D
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (8 in all)
See the 1 study
-
The Role of Glutamine in the Aetiology of the Chronic Fatigue Syndrome (1998)
- People in the study
- 16 randomised
- Dose
- 2000 mg, daily
- Outcome
- Emotionality
- Effect
- no clear difference
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Sleep1 study · 8 (few people) people took glutamine Little or no difference D
Why this grade: Little or no difference, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (8 in all).
Studies with no comparison group16 randomised · 26 weeks · 2000 mg, daily (few people)
No clear change in sleep.
The evidence is very uncertain about the effect of glutamine on sleep in ME/CFS. Little or no difference · very low certainty D
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (8 in all)
See the 1 study
-
The Role of Glutamine in the Aetiology of the Chronic Fatigue Syndrome (1998)
- People in the study
- 16 randomised
- Dose
- 2000 mg, daily
- Outcome
- Sleep Problems
- Effect
- no clear difference
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Studies of combinations
Outcomes that only studies of glutamine given together with other treatments looked at. Shown, not graded: they can’t tell what glutamine did alone.
Overall symptoms ME/CFS
Combination: Glutamine + NAC (N-acetylcysteine) + Zinc + Leaky gut protocol and supplements + L-carnitine + CoQ10 / ubiquinol + Taurine + Alpha-lipoic acid (ALA, R-ALA) + Turmeric / curcumin + Baicalein and quercetin41 in the study
Normalization of leaky gut in chronic fatigue syndrome (CFS) is accompanied by a clinical improvement: effects of age, duration of illness and the translocation of LPS from gram-negative bacteria. (2008): Fibromyalgia and Chronic Fatigue Syndrome Rating Scale (FF scale), better (not tested).
Shown, not counted: glutamine was given together with other treatments.
Side effects
No study of this treatment alone reported side effects we could read.
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
2000 mg at the start
- 2Top dose
Most often 2000 mg (1 of 1 studies)
Doses across 1 study
2000 to 2000 mg.
Each study’s dose, as printed
- 2000 mg, daily The Role of Glutamine in the Aetiology of the Chronic Fatigue Syndrome (1998)
All papers
- The Role of Glutamine in the Aetiology of the Chronic Fatigue Syndrome1998 · placebo trial · 16 randomised
Summary
Sixteen people with chronic fatigue syndrome (CFS) and 16 age- and sex-matched healthy controls took part. The CFS subjects were randomly assigned to L-glutamine or placebo, 2000 mg oral daily for 26 weeks, double-blind. The trial compared glutamine status and tested whether L-glutamine changed symptoms. It measured plasma and muscle glutamine and symptom scores from an eighteen-point questionnaire, and recorded upper respiratory tract infections. In the L-glutamine group (n = 8), plasma glutamine rose from 803 to 905 (P = 0.020) and muscle glutamine from 17.5 to 20.1 (P = 0.037). The placebo group (n = 8) had no significant increases (P > 0.05). The L-glutamine group reported no significant changes in any of the five symptom categories (P > 0.05). The placebo group had significant decreases in emotionality (P = 0.02) and sleep problems (P = 0.02), and not significant decreases in general fatigue, concentration difficulties and physical complaints. Six of the sixteen CFS subjects (38%) met the recovery criterion at week 26, two from L-glutamine and four from placebo. No adverse side effects were observed in any CFS subjects during the trial; two subjects reported a relapse after the trial.
- Improvement in Long COVID Brain Fog After Benfotiamine and Methylcobalamin Supplementation: Case Report Series and Review of the Literature2026 · case report · 3 in the study
Summary
This case series reports three people with Long COVID-related cognitive dysfunction (brain fog); one also had chronic fatigue syndrome/myalgic encephalomyelitis. All three self-administered an oral proprietary formulation of benfotiamine and methylcobalamin at differing doses: benfotiamine 150 mg, 300 mg, or 300 mg twice daily, with methylcobalamin 500 mcg, 1,000 mcg, or 12 mcg per day. There was no comparison group. Outcomes were patient-reported; no baseline thiamine or vitamin B12 biomarkers and no cognitive assessments were obtained before supplementation. Each patient described a noticeable benefit within a brief period ranging from several days to several weeks. In case 1, improvement in energy and mental clarity and resolution of brain fog were reported within three days. In case 2, improvements in mental clarity, executive function and confidence were reported within six weeks; after five weeks without the supplement, cognitive dysfunction recurred, and improved cognitive function returned within four to six weeks of resuming it. In case 3, brain fog and joint pain improved within 10 days, radicular pain resolved and dizziness improved by approximately 85% after 30 days. No serious adverse effects were reported by any patient; case 1 reported no adverse effects. The authors state the observations are hypothesis-generating and cannot establish causality.
- Attenuation of autoimmune responses to oxidative specific epitopes, but not nitroso-adducts, is associated with a better clinical outcome in Myalgic Encephalomyelitis/chronic fatigue syndrome.2014 · combination: given with other treatments · 76 in the study
Summary
Seventy-six ME/CFS patients admitted to the Maes Outpatient Clinics, Belgium, were selected for increased (> 2 SD) IgM responses to 3 OSEs or 3 NO-adducts. In this non-interventional study, all patients took a combination of NAIOS—L-carnitine, coenzyme Q10, taurine + lipoic acid, with or without curcumine + quercitine or N-acetyl-cysteine, zinc + glutamine—continued for 14.3 (±4.2) months. There was no separate comparison group; patients also received other care-as-usual treatments. The study measured FF scores and IgM responses to oleic acid, MDA, Pi, NOW, NO-arginine and NO-cysteinyl. Treatment was followed by significant reductions in IgM responses to oleic acid (F=9.03, p=0.004), MDA (F=13.12, p=0.001), Pi (F=20.28, p<0.001), NO-Cysteinyl (F=10.03, p=0.003), NO-Arginine (F=6.99, p=0.011) and NOW (F=6.19, p=0.016). In patients with endpoint FF<12, oleic acid and Pi responses fell more than in those with endpoint FF≥12. Antidepressant use had no significant effect (F=0.17, p=0.843). Harms were not reported. The authors state the non-interventional design could not standardize NAIOS and that supplement quality, content and bioavailability may have biased results.
- Normalization of leaky gut in chronic fatigue syndrome (CFS) is accompanied by a clinical improvement: effects of age, duration of illness and the translocation of LPS from gram-negative bacteria.2008 · combination: given with other treatments · 41 in the study
Summary
This non-interventional study asked whether gut-derived LPS translocation and clinical severity change in chronic fatigue syndrome. Forty-one patients were consecutively admitted to the M-Care4U Outpatient Clinics, Belgium, and selected for initial increases in IgM and/or IgA responses to LPS. All followed a leaky gut diet and took glutamine, zinc and NAC, plus other NAIOSs (L-carnitine, coenzyme Q10, taurine, lipoic acid, curcumine, quercitine) for 10-12 months (also reported as 10-14 months). There was no comparison group; before and endpoint measures were compared. Outcomes included the Fibromyalgia and Chronic Fatigue Syndrome Rating Scale (FF scale) and IgM/IgA responses to LPS. The mean FF score was 38.8 at baseline and 14.0 at endpoint. Overall, 26 (63.5%) patients showed a good clinical response, while 15 (36.5%) showed less clinical improvement. At endpoint, responders had FF 7.7 versus non-responders 24.9; patients ill <5 years had 7.3 versus >5 years 18.7; age <38 years had 10.6 versus >38 years 17.6. The overall age comparison was not significant (p=0.2). Side effects and withdrawals were not reported.
- Normalization of the increased translocation of endotoxin from gram negative enterobacteria (leaky gut) is accompanied by a remission of chronic fatigue syndrome.2007 · combination: given with other treatments · 1 in the study
Summary
This case report from Belgium describes one 13-year-old girl with chronic fatigue syndrome (CFS) who was unable to walk or stand and had muscle pain and weakness. She received a combined treatment: antioxidants (L-carnitine, CoQ10, lipoic acid, taurine), a supplement containing L-glutamine, gamma oryzanol and zinc, a specific “leaky gut diet”, and intravenous immunoglobulins (IVIg; sandoglobuline 6 g/day during 1 month, and thereafter 6 g each two weeks for the following months). No comparison group was reported. The paper reports clinical symptoms and serum IgM against the LPS of gram-negative bacteria. During December 2005 to May 2006, no change in the clinical picture could be detected. On August 18, 2006, she regained strength, her concentration was much better and she could read books again, her sleep disorders were much better, and she had restarted swimming classes; she still suffered from non-refreshing sleep and abdominal complaints. On December 8, 2006, her clinical condition was again much better, her sleep became refreshing, and abdominal complaints including bloating were better, although sometimes she had diarrhea and nausea; during one week she had suffered from sore throat and tender lymph nodes. On February 1, 2007, she ascertained that all her symptoms had disappeared. IVIg was stopped, while antioxidants and the leaky gut diet were continued. On July 13, 2007, she finished the school year with a very good score (>80%). By November, 2007, all CFS symptoms were still in remission. No limitations were stated in the supplied text.
- Role of dietary modification in alleviating chronic fatigue syndrome symptoms: a systematic review.2017 · systematic review
Summary
This systematic review asked whether dietary modification alleviates chronic fatigue syndrome (CFS) or myalgic encephalomyelitis (ME) symptoms. It searched Scopus, CINAHL Plus, Web of Science and PsycINFO from 1994 to 2014 in May 2014, with an update from June 2014 to August 2016, and included 22 studies across animal and human designs. Treatments included D-ribose, probiotic, oral vitamin D3, vitamin and mineral supplements, polynutrient supplementation, magnesium, calcium, ginseng, EFA supplements, glutamine, a low-sugar low-yeast diet, and polyphenols (AMF, EGCG, naringin). D-ribose showed significant improvement in energy levels in compliant analysis (p<0.0001, 95%CI 1.1–2.2), and 65.7% reported improved overall subjective feelings. Probiotic: six of 15 reported subjective improvement and neurocognitive measures improved (p=0.04), but no significant overall change. Vitamin D3 showed no statistically significant improvement in fatigue or inflammatory/oxidative markers. One vitamin/mineral supplement showed improvements in fatigue (p=0.0009) and some quality-of-life measures; another found no significant relationship. Polynutrient supplementation found no significant results. Magnesium improved fatigue at six months (p=0.002) but not at two years; calcium improved fatigue (p=0.01) based on five participants; ginseng was most helpful in 56%. An EFA case study dropped depression scores from 27 to 3 at 16 weeks; an EFA versus sunflower-oil placebo trial found no significant difference. Glutamine showed no significant symptom change; placebo showed decreases in emotionality and sleep problems (p=0.02). The low-sugar low-yeast diet showed no significant difference. Animal polyphenol studies reported significant improvements (p<0.05). The review did not report side effects or withdrawals.
- Myalgic encephalomyelitis/chronic fatigue syndrome: From pathophysiological insights to novel therapeutic opportunities.2019 · review
Summary
This review asks why pathophysiological insights in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) might point to treatments, and it examines treatment data for antioxidant and anti-inflammatory options. It reports no primary enrolment or analysis; it discusses patients diagnosed with ME/CFS by international consensus or Fukuda criteria and reviews CBT, GET, curcumin, NAC, CoQ10, melatonin, probiotics/prebiotics and molecular hydrogen. For the PACE trial, it reports that a year of CBT produced modest and short-term reductions in fatigue of some 10% compared with an untreated control group and a non-significant worsening of distance walked in six minutes. It also reports that CBT and GET reduced self-reported fatigue by some 13% compared with no treatment after 52 weeks, that GET improved six-minute walking distance by 31m compared with no treatment, and that GET for 12 months was associated with a 67m improvement versus 22m with specialist medical care alone. In 60 patients selected by international consensus criteria, graded exercise over a 12-month period was reported to worsen physical function and pain. Hydrogen-rich water studies in Parkinson’s disease (1,000 mL/day over a 48-week period) and rheumatoid arthritis (500 mL of 1 ppm for four weeks) reported improvements versus controls. The authors state these data are promising yet preliminary.